跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
XERMELO - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
XERMELO
Authorized
STANDARD
XERMELO
SERB SAS
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
c19cb224f9fea454
Company
SERB SAS
Type
Standard
Approval Details
Approval Id
c19cb224f9fea454
Drug Approval Canada Name
XERMELO
Product Name
XERMELO
Status
Marketed
Status Date
2024-07-02
Original Market Date
2018-12-07
Din
02481553
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
56:08.00
Atc Original
A16AX15 TELOTRISTAT
Atc Name
a 16 ax 15
Aig Number
0160731001
Company Name
SERB SAS
Company Address
40 Avenue George V, Paris, --, France, 75008
Company Detail Path
/organization/serb-sas
Company Information
Pharmaceutical Company Name
SERB SAS
Country Name
France
Active Ingredients
TELOTRISTAT ETHYL (TELOTRISTAT ETIPRATE)
250 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
c19cb224f9fea454
Type
Standard
Back to Health Canada Approvals